Search Tag: preserved ejection fraction

Cardiology Management

Esccongress-results-of-the-emperor-preserved-trial

2021 27 Aug

In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction.   This was a pooled analysis of two randomised trials that investigated the beneficial effects of...Read more

Cardiology Management

Esccongress-preview-paragon-hf-trial

2019 10 Aug

Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.  The  PARAGON-HF trial  in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more

Cardiology Management

Esc2019-preview-paragon-hf-trial

2019 03 Aug

Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.  The PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator...Read more